SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Letter to the Editor

Split Viewer

Blood Res 2019; 54(1):

Published online March 31, 2019

https://doi.org/10.5045/br.2019.54.1.77

© The Korean Society of Hematology

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib

Jun Ho Yi1*, and Hye Ryoun Kim2

Author Info. +

1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.

2Department of Laboratory Medicine, Chung-Ang University, Seoul, Korea.

Correspondence to : Jun Ho Yi. Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Heuksuk-ro 102, Dongjak-gu, Seoul 06973, Korea. xuno@cau.ac.kr

Received: July 10, 2018; Revised: October 18, 2018; Accepted: October 29, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

FIGURES

Go to
Fig. 1.

Bone marrow biopsy specimens at the time of diagnosis (hematoxylin and eosin stain, ×400). Atypical megakaryocytes showing cloud-like nuclei with a high nucleusto-cytoplasm ratio (A). Dense clusters of megakaryocytes (B).


Fig. 2.

Clinicolaboratory course of the patient. a)Number of Ph+ cells/number of analyzed cells by chromosome analysis; b)Number of Ph+ cells/number of analyzed cells by fluorescence in situ hybridization analysis. Ph+, Philadelphia chromosome-positive.


REFERENCES

Go to
  1. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC Press.
  2. Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106-4107.
  3. Krämer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007;8:658-660.
    Pubmed
  4. Bornhäuser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007;21:1824-1826.
    Pubmed
  5. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007;21:1103-1104.
    Pubmed
  6. Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008;22:1454-1455.
    Pubmed
  7. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011;117:e198-e206.
    Pubmed
  8. Pieri L, Spolverini A, Scappini B, et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood 2011;118:3445-3446.
    Pubmed
  9. Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 2015;5:e351.
    Pubmed
  10. Iurlo A, Gianelli U, Rapezzi D, et al. Imatinib and ruxolitinib association: first experience in two patients. Haematologica 2014;99:e76-e77.
    Pubmed

Article

Letter to the Editor

Blood Res 2019; 54(1): 77-79

Published online March 31, 2019 https://doi.org/10.5045/br.2019.54.1.77

Copyright © The Korean Society of Hematology.

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib

Jun Ho Yi1*, and Hye Ryoun Kim2

1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Seoul, Korea.

2Department of Laboratory Medicine, Chung-Ang University, Seoul, Korea.

Correspondence to: Jun Ho Yi. Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Heuksuk-ro 102, Dongjak-gu, Seoul 06973, Korea. xuno@cau.ac.kr

Received: July 10, 2018; Revised: October 18, 2018; Accepted: October 29, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Fig 1.

    Download
    Figure 1.

    Bone marrow biopsy specimens at the time of diagnosis (hematoxylin and eosin stain, ×400). Atypical megakaryocytes showing cloud-like nuclei with a high nucleusto-cytoplasm ratio (A). Dense clusters of megakaryocytes (B).

    Blood Research 2019; 54: 77-79https://doi.org/10.5045/br.2019.54.1.77

    Fig 2.

    Download
    Figure 2.

    Clinicolaboratory course of the patient. a)Number of Ph+ cells/number of analyzed cells by chromosome analysis; b)Number of Ph+ cells/number of analyzed cells by fluorescence in situ hybridization analysis. Ph+, Philadelphia chromosome-positive.

    Blood Research 2019; 54: 77-79https://doi.org/10.5045/br.2019.54.1.77

    References

    1. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC Press.
    2. Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106-4107.
    3. Krämer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 2007;8:658-660.
      Pubmed
    4. Bornhäuser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007;21:1824-1826.
      Pubmed
    5. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007;21:1103-1104.
      Pubmed
    6. Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008;22:1454-1455.
      Pubmed
    7. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011;117:e198-e206.
      Pubmed
    8. Pieri L, Spolverini A, Scappini B, et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood 2011;118:3445-3446.
      Pubmed
    9. Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 2015;5:e351.
      Pubmed
    10. Iurlo A, Gianelli U, Rapezzi D, et al. Imatinib and ruxolitinib association: first experience in two patients. Haematologica 2014;99:e76-e77.
      Pubmed
    Blood Res
    Volume 59 2024
    Current Issue Archives

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download